Leerink Partnrs Estimates Vaxcyte FY2029 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Investment analysts at Leerink Partnrs issued their FY2029 EPS estimates for Vaxcyte in a research note issued on Sunday, January 12th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings per share of $2.42 for the year. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and an average target price of $145.71.

Vaxcyte Price Performance

NASDAQ PCVX opened at $78.14 on Tuesday. The stock has a market capitalization of $9.74 billion, a P/E ratio of -16.99 and a beta of 0.98. The business has a 50 day simple moving average of $89.10 and a 200 day simple moving average of $93.56. Vaxcyte has a one year low of $58.10 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the company earned ($0.91) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its position in shares of Vaxcyte by 23.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after buying an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. increased its position in shares of Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after acquiring an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Vaxcyte by 47.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after acquiring an additional 419,600 shares during the period. Point72 Asset Management L.P. purchased a new position in Vaxcyte in the third quarter worth $41,114,000. Finally, Maverick Capital Ltd. grew its stake in Vaxcyte by 93.7% in the 2nd quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock valued at $51,944,000 after purchasing an additional 332,777 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $106.82, for a total transaction of $1,602,300.00. Following the transaction, the chief executive officer now directly owns 435,219 shares in the company, valued at approximately $46,490,093.58. This trade represents a 3.33 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total transaction of $457,450.00. Following the completion of the sale, the senior vice president now owns 28,697 shares of the company’s stock, valued at approximately $2,625,488.53. The trade was a 14.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 113,732 shares of company stock worth $11,730,787. Insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.